Kyowa KirinOfficial website ↗Pioneering Specialty Pharmaceuticals for Under-Served Diseases. We combine global talent and innovation to deliver life-changing medicines that make people smile. Source: https://kyowakirininternational.com/who-we-are1 medicine explainedburosumabCrysvitaFGF23-blocking antibodyCrysvita (burosumab) is a monoclonal antibody from Kyowa Kirin that neutralises FGF23, the hormone that wastes phosphate through the kidneys. By restoring phosphate balance it treats X-linked hypophosphataemia and tumour-induced osteomalacia, conditions that weaken bones.Phosphate is a mineral the body needs to build strong bones. In X-linked hypophosphataemia and tumour-induced osteomalacia, too much of the hormone FG
